CD Genomics launches viral genome sequencing services within the Illumina and PacBio platforms, generating large viral genomes with high-quality de novo assembly and the highest data quality at low cost. Comprehensive viral sequences will facilitate the interpretation of viral macro-genomics data by providing reference genomes, leading to a better understanding of viral diversity, ecology, adaptation and evolution, and the ability to predict emerging infectious diseases caused by viruses.
Viruses are the most abundant biological entities on the planet and can adversely impact animals and human beings by causing disease and shaping the immune systems. Despite their ubiquity and impact, less than 0.01% of existing viruses have been sequenced. Research into the pathogenesis of viral diseases and the development of new therapies is currently undergoing rapid change. One commonly used NGS platform, Illumina, recommends a maximum read length of approximately 300-500 nucleotides for analysis. Recently, PacBio single-molecule real-time sequencing has improved the sequencing standards by enabling complete long reads and largely reducing errors.
The Laboratory of Retroviruses of the Food and Drug Administration has conducted in-depth research on the biological and genomic characteristics of the African green monkey simian foamy virus, and elucidated the host range, cell tropism, and virus replication regulation. The viral nucleic acid prepared from SFVcae_FV2014 virus stock was sequenced using the MiSeq Illumina platform by CD Genomics.
CD Genomics’s sequencing solutions can address the need to sequence a variety of viruses, such as ssDNA, dsDNA, ssRNA and dsRNA viruses. At this time of a global pandemic, CD Genomics hopes to do their part in the fight against viruses by revealing more about them through sequencing technology.
“Our platform allows for the complete and accurate sequencing of the viral genome and the identification of minor mutations. Our sequencing platform balances sequencing depth and high throughput to provide researchers with high-quality yet cost-effective data. Meanwhile, our Illumina platform and long-read sequencing platform can provide researchers with more options.”
